Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tecovirimat is active against various MPXV strains, while cidofovir, brincidofovir, trifluridine, and gemcitabine have no detectable MPXV-specific antiviral activity

12 Aug 2025

Abstract excerpt

In treating patients with mpox, current treatment options are limited, with tecovirimat (TEC) being one of the few available. TEC has been approved by the European Medicines Agency (EMA) for treating patients with mpox and is in clinical use in Europe and Japan. However, following exposure to TEC, TEC-resistant variants such as A290V-containing variant (MPXV R TEC/A290V ) emerge quickly. In such cases involving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus Infections and Treatments
Share to Poxvirus research and outbreaks
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40812450
DOI: 10.1016/j.virusres.2025.199615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tecovirimat is active against various MPXV strains, while cidofovir, brincidofovir, trifluridine, and gemcitabine have no detectable MPXV-specific antiviral activityPMID 40812450Read ↗

Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub-lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatmentSemantic proximity Read ↗

Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub-lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment.Semantic proximity Read ↗

Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.Semantic proximity Read ↗

Mechanisms of Tecovirimat Antiviral Activity and Poxvirus ResistanceSemantic proximity Read ↗

Potential therapeutic targets for Mpox: the evidence to dateSemantic proximity Read ↗

Repurposing Drugs for Synergistic Combination Therapies to Counteract Monkeypox Virus Tecovirimat ResistanceSemantic proximity Read ↗

Novel derivatives of brincidofovir and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine inhibit orthopoxviruses and human adenoviruses more potently than brincidofovirSemantic proximity Read ↗

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023Semantic proximity Read ↗

Resistance to anti-orthopoxviral drug tecovirimat (TPOXX<sup>®</sup>) during the 2022 mpox outbreak in the USSemantic proximity Read ↗

In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individualsSemantic proximity Read ↗

The mechanism of Micafungin action to Pteropine orthoreovirus infection in human cell lineSemantic proximity Read ↗

Structural insights into tecovirimat antiviral activity and poxvirus resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.